Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pharmathene Buys Avecia Vaccines Unit

March 31, 2008 | A version of this story appeared in Volume 86, Issue 13

PharmAthene of Annapolis, Md., has agreed to pay $20 million to acquire Avecia Biologics' biodefense vaccines business. The deal includes a second-generation recombinant protective antigen (rPA) anthrax vaccine, a recombinant dual-antigen plague vaccine, and a third-generation rPA anthrax vaccine. Roughly 50 employees from Avecia's U.K. office will become PharmAthene employees. Avecia will supply the drugs under a long-term agreement and could receive an additional $20 million in milestone payments as well as royalties if PharmAthene wins vaccine contracts. Avecia, which sold the small-molecule piece of its contract manufacturing business to India's Nicholas Piramal in 2005, will now focus on microbial biologics and oligonucleotides.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.